Genetic susceptibility of opioid receptor genes polymorphism to drug addiction: A candidate-gene association study
- PMID: 33402148
- PMCID: PMC7786995
- DOI: 10.1186/s12888-020-03006-z
Genetic susceptibility of opioid receptor genes polymorphism to drug addiction: A candidate-gene association study
Abstract
Background: Like other complex diseases including drug addiction, genetic factors can interfere with the disease. In this study, three opioid genes (OPRM1, OPRD1, and OPRK1) were examined for an association with drug addiction among Jordanian males.
Methods: The study involved 498 addicts, in addition to 496 healthy controls and all from Arab descent.
Results: The findings in this study showed that rs1799971 of the OPRM1 gene was in association with drug addiction for both alleles and genotypes with P-values = 0.002 and 0.01, respectively. In addition, a significant association between the dominant model (A/A vs G/A-G/G) of rs1799971 (OPRM1) and drug addiction (P-value = 0.003, OR = 1.59 (1.17-2.15)) was detected. Moreover, a genetic haplotype (AGGGCGACCCC) of theOPRM1 gene revealed a significant association with drug addiction (P-value = 0.01, OR = 1.56 (1.15-2.12)). We also found that the age of addicts, smoking, and marital status with genetic variants within OPRM1, OPRD1, and OPRK1 genes may be implicated in drug addiction risk.
Conclusion: We propose that rs1799971 of the OPRM1gene is a genetic risk factor for drug addiction among Jordanian males.
Keywords: Drug addiction; Jordan; Opioids; Polymorphism.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Contribution of Genetic Polymorphisms and Haplotypes in DRD2, BDNF, and Opioid Receptors to Heroin Dependence and Endophenotypes Among the Han Chinese.OMICS. 2017 Jul;21(7):404-412. doi: 10.1089/omi.2017.0057. OMICS. 2017. PMID: 28692418
-
The association between the OPRM1 A118G polymorphism and addiction in a Turkish population.Arh Hig Rada Toksikol. 2019 Jun 1;70(2):97-103. doi: 10.2478/aiht-2019-70-3153. Arh Hig Rada Toksikol. 2019. PMID: 31246565
-
A118G mu opioid receptor polymorphism among drug addicts in Malaysia.J Integr Neurosci. 2012 Mar;11(1):117-22. doi: 10.1142/S0219635212500082. J Integr Neurosci. 2012. PMID: 22744787
-
Pharmacogenomics of the human µ-opioid receptor.Pharmacogenomics. 2011 Sep;12(9):1305-20. doi: 10.2217/pgs.11.68. Pharmacogenomics. 2011. PMID: 21919606 Review.
-
Lack of associations of the opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with alcohol dependence: review and meta-analysis of retrospective controlled studies.BMC Med Genet. 2017 Oct 26;18(1):120. doi: 10.1186/s12881-017-0478-4. BMC Med Genet. 2017. PMID: 29070014 Free PMC article. Review.
Cited by
-
Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?J Pers Med. 2022 Oct 14;12(10):1719. doi: 10.3390/jpm12101719. J Pers Med. 2022. PMID: 36294858 Free PMC article.
-
Genomic factors associated with substance use disorder relapse: A critical review.Addict Behav Rep. 2024 Oct 30;20:100569. doi: 10.1016/j.abrep.2024.100569. eCollection 2024 Dec. Addict Behav Rep. 2024. PMID: 39553284 Free PMC article. Review.
-
A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System.Biomedicines. 2025 Jan 11;13(1):165. doi: 10.3390/biomedicines13010165. Biomedicines. 2025. PMID: 39857749 Free PMC article. Review.
-
Inhibitory effects of the selective μ-opioid receptor antagonist UD-030 on methamphetamine-induced conditioned place preference.Neuropsychopharmacol Rep. 2025 Mar;45(1):e12503. doi: 10.1002/npr2.12503. Epub 2024 Nov 27. Neuropsychopharmacol Rep. 2025. PMID: 39601072 Free PMC article.
-
A systems omics-based approach to decode substance use disorders and neuroadaptations.Neurosci Biobehav Rev. 2021 Nov;130:61-80. doi: 10.1016/j.neubiorev.2021.08.016. Epub 2021 Aug 17. Neurosci Biobehav Rev. 2021. PMID: 34411560 Free PMC article. Review.
References
-
- AL-Eitan L, Tarkhan A. Practical challenges and translational issues in pharmacogenomics and personalized medicine from 2010 onwards. Curr Pharmacogenom Personalized Med. 2016;14:7–17. doi: 10.2174/1875692115666161215103842. - DOI
-
- Al-Eitan LN, Jaradt SA, Hulse GK, Tay GK. Pharmacogenetic approach to treating drug dependence: serotonin transporter gene (SLC6A4) promoter polymorphisms as treatment predictors in Jordanian Arabs. Curr Pharmacogenomics Pers Med. 2012;10:293–305. doi: 10.2174/187569212803901783. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases